Cancers, Vol. 11, Pages 11: Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials

In conclusion, 96.5% of patients with hematologic malignancies have adequate tissue for comprehensive genomic profiling. Most patients had unique molecular signatures, and 75% had alterations that may be pharmacologically tractable with gene- or immune-targeted agents.

Source: Cancers - December 21, 2018 Category: Cancer & Oncology Authors: Natalie Galanina Rafael Bejar Michael Choi Aaron Goodman Matthew Wieduwilt Carolyn Mulroney Lisa Kim Huwate Yeerna Pablo Tamayo Jo-Anne Vergilio Tariq I. Mughal Vincent Miller Catriona Jamieson Razelle Kurzrock Tags: Article Source Type: research